Summary
Current radiotherapy is fully reliant on semi-automatic treatment planning systems (TPS) that depend on highly toxic CT scans and human clinical expertise for creating a treatment plan. As a result, the procedure is inefficient and inefficacious resulting in poor treatment outcome and severe side effects. In recent years, there has been an emergence of the concept of MRI-guided radiotherapy, wherein non-toxic and high resolution MRI images are used to guide treatment planning. As a result, several key players in the radiotherapy market such as Elekta and ViewRay have introduced MRI embedded linear acclerators to perform MRI imaging during radiotherapy administration. However, as of yet no TPS exists on the market that enables fully automated MRI-guided radiotherapy, in order to provide real-time dose adjustment.
To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.
In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.
To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.
In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/880314 |
| Start date: | 01-11-2019 |
| End date: | 31-07-2022 |
| Total budget - Public funding: | 3 539 583,00 Euro - 2 477 708,00 Euro |
Cordis data
Original description
Current radiotherapy is fully reliant on semi-automatic treatment planning systems (TPS) that depend on highly toxic CT scans and human clinical expertise for creating a treatment plan. As a result, the procedure is inefficient and inefficacious resulting in poor treatment outcome and severe side effects. In recent years, there has been an emergence of the concept of MRI-guided radiotherapy, wherein non-toxic and high resolution MRI images are used to guide treatment planning. As a result, several key players in the radiotherapy market such as Elekta and ViewRay have introduced MRI embedded linear acclerators to perform MRI imaging during radiotherapy administration. However, as of yet no TPS exists on the market that enables fully automated MRI-guided radiotherapy, in order to provide real-time dose adjustment.To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.
In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
